常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-18.62/-6.35
|
|
企業價值
26.61M
|
| 資產負債 |
|
每股賬面淨值
-6.04
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
398.00K
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||
|
||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Lyra Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of anti-inflammatory therapies for the localized treatment of patients with chronic rhinosinusitis, or CRS. Its products include LYR-210 and LYR-220. The company operates in a single operating segment, which is the business of developing targeted medicines to address ear, nose, and throat, or ENT, diseases. |

0.8046 
